UNSPSC 51402003: Meprobamate

This classification denotes a sedative, hypnotic, and anticonvulsant agent with the molecular formula C9H18N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9I7LNY769Q, chemically known as 1,3-propanediol, 2-methyl-2-propyl-, carbamate isopropylcarbamate (ester) but generally known as meprobamate, which bears US NIH Compound Identifier 2576. European Medicines Agency schedules Meprobamate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08757MIG.

UNSPSC 51402003 Meprobamate, a Commodity code, nominally names a single anxiolytic pharmaceutical product, but recent state and local procurement activity under this code shows little alignment with that narrow scope. Instead, the opportunities tagged to this code reflect broader pharmaceutical procurement: Seminole County, Florida solicited naloxone and drug deactivation systems through an IFB; the Texas Health and Human Services Commission issued an RFI to explore direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager channels; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released an RFP for generic multi-source pharmaceuticals and OTC products across participating state and local jurisdictions. The issuing bodies span county health departments, state HHS agencies, and cooperative purchasing vehicles serving multiple states. The mismatch between the code name and actual procurement suggests that meprobamate may be grouped taxonomically with broader pharmaceutical categories in state and local systems, or that recent opportunities are miscoded at the commodity level.

Geographic activity centers on Florida, Texas, and Minnesota with multistate reach through MMCAP's network including Oregon. Seminole County's IFB (IFB60459723LAS, due July 26, 2023) targets 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, fixed-fee pricing, a two-year initial term with one-year renewal option, and potential FEMA funding. The Texas HHS RFI (HHS0017013, posted April 3, 2026) seeks vendor capabilities for direct manufacturer contracting to optimize prescription fulfillment and cost management outside existing PBM and GPO structures. MMCAP's RFP (S1070000015802, due March 26, 2026) establishes multi-state contracts for generic pharmaceuticals and OTC products effective July 1, 2026, with pricing weighted at 75 percent, requirement for cGMP and DSCSA certification, mandatory relationships with two of three authorized wholesalers (Cencora, Cardinal Health, Morris & Dickson), and 3 percent administrative fees on purchases. The scope divergence and thin recent-opportunity set under this specific commodity code signal limited direct relevance for meprobamate vendors; activity appears concentrated in larger pharmaceutical supply and program-design initiatives rather than single-drug procurement.